Semma Therapeutics

Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
Show more
Parent CompanyVertex Pharmaceuticals
HQCambridge, MA, US
Cybersecurity ratingAMore
Semma Therapeutics was founded in 2015 and is headquartered in Cambridge, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Semma Therapeutics

Bastiano Sanna

Bastiano Sanna

David Lebwohl

David Lebwohl

Chief Medical Officer
David DiGiusto

David DiGiusto

Mary Kay Fenton

Mary Kay Fenton

Felicia Pagliuca

Felicia Pagliuca

Scientific Co-Founder, Vice President of Cell Biology Research and Development
Christopher G. Thanos

Christopher G. Thanos

Vice President, Delivery
Show more

Semma Therapeutics Office Locations

Semma Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
100 Technology Square Floor 3
Cambridge, MA, US
450 Kendall St #2b
Show all (2)

Semma Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$163 m


In total, Semma Therapeutics had raised $163 m. Semma Therapeutics is a subsidiary of Vertex Pharmaceuticals

Semma Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Semma Therapeutics Online and Social Media Presence

Embed Graph

Semma Therapeutics Blogs

Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

-Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired for $950 million in cash- CAMBRIDGE, Mass., September 3, 2019 – Vertex Pharmaceutica…

Semma Therapeutics Announces Pre-Clinical Proof-of-Concept in Two Lead Programs in Type 1 Diabetes

– Stem cell-derived islets successfully reduce insulin requirements in diabetic non-human primates – – Novel device successfully protects stem cell-derived islets in pigs without immunosuppression – – Company plans to initiate two clinical trials in 2020 – CAMBRIDGE, Mass., July 1, 2019 – Semma The…

Semma Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer

CAMBRIDGE, Mass., May 29, 2019 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced that it has expanded its leadership team with the addition of Mary Kay Fenton as Chief Financial Officer. “I am absolutely thrilled…

Semma Therapeutics Announces Publication in Nature Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes

CAMBRIDGE, Mass., May 8, 2019 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the journal Nature published data demonstrating improvements in the production of beta cells (cells that produce insulin) from stem c…

Semma Therapeutics Frequently Asked Questions

  • When was Semma Therapeutics founded?

    Semma Therapeutics was founded in 2015.

  • Who are Semma Therapeutics key executives?

    Semma Therapeutics's key executives are Bastiano Sanna, David Lebwohl and David DiGiusto.

  • How many employees does Semma Therapeutics have?

    Semma Therapeutics has 88 employees.

  • Who are Semma Therapeutics competitors?

    Competitors of Semma Therapeutics include InVivo Therapeutics, Gan & Lee Pharmaceuticals and Viatris.

  • Where is Semma Therapeutics headquarters?

    Semma Therapeutics headquarters is located at 100 Technology Square Floor 3, Cambridge.

  • Where are Semma Therapeutics offices?

    Semma Therapeutics has an office in Cambridge.

  • How many offices does Semma Therapeutics have?

    Semma Therapeutics has 2 offices.